Search bioRxiv⌕ Search

Biology subjects

Childs, H.

Publications and source records attributed to Childs, H..

2 recordsLinked to original sources

Has AlphaFold 3 Solved the Protein Folding Problem for D-Peptides?

Due to their favorable therapeutic properties, including improved stability, bioavailability, and membrane permeability, D-peptides that bind biological L-proteins represent an important class of systems in computational drug design. A reliable in silico workflow for these systems must correctly preserve stereochemistry while predicting fold and binding pose. The AlphaFold 3 (AF3) model reported by Abramson et al. (2024) enforces a strict chirality violation penalty to maintain chiral centers from model inputs and is reported to have a low chirality violation rate of only 4.4% on a PoseBusters benchmark containing diverse chiral molecules. Herein, we report the results of 3,255 black-box experiments with AF3 to evaluate its ability to predict the fold, chirality, and binding pose of D-peptides in heterochiral complexes. Despite inputs specifying explicit D-stereocenters, we report that the AF3 chirality violation rate for D-peptide binders is much higher at 51% across all evaluated predictions; on average the model is as accurate as chance (random chirality choice, L or D, for each peptide residue). Increasing the number of seeds failed to improve this violation rate. The AF3 predictions exhibit incorrect folds and binding poses, with D-peptides commonly oriented incorrectly in the L-protein binding interface. Confidence metrics returned by AF3 also fail to distinguish predictions with low chirality violation and correct docking vs. predictions with high chirality violation and incorrect docking. We conclude that AF3 is a poor predictor of D-peptide chirality, fold, and binding pose and propose solutions to address these limitations. Significance StatementAlphaFold 3 (AF3) is a model trained to predict protein interactions. This algorithm is tuned to respect chiral centers (L and D). Changing the chirality of even one protein residue can significantly alter chemical properties such as binding and stability. Therefore, an algorithm should exhibit a chiral center error rate of 0%. Although the original AF3 authors reported a 4.4% chirality violation rate, we have found that the rate for D-peptides is much higher at[~] 50%. Our data reveal a crucial structural prediction error in AF3 and demonstrate that this widely used model is as accurate on average as chance (random chirality choice, L or D, for each peptide residue). These results indicate structure prediction of D-peptides is an outstanding problem.

bioinformatics↗

DexDesign: A new OSPREY-based algorithm for designing de novo D-peptide inhibitors

With over 270 unique occurrences in the human genome, peptide-recognizing PDZ domains play a central role in modulating polarization, signaling, and trafficking pathways. Mutations in PDZ domains lead to diseases such as cancer and cystic fibrosis, making PDZ domains attractive targets for therapeutic intervention. D-peptide inhibitors offer unique advantages as therapeutics, including increased metabolic stability and low immunogenicity. Here, we introduce DexDesign, a novel OSPREY-based algorithm for computationally designing de novo D-peptide inhibitors. DexDesign leverages three novel techniques that are broadly applicable to computational protein design: the Minimum Flexible Set, K*-based Mutational Scan, and Inverse Alanine Scan, which enable exponential reductions in the size of the peptide sequence search space. We apply these techniques and DexDesign to generate novel D-peptide inhibitors of two biomedically important PDZ domain targets: CAL and MAST2. We introduce a new framework for analyzing de novo peptides--evaluation along a replication/restitution axis--and apply it to the DexDesign-generated D-peptides. Notably, the peptides we generated are predicted to bind their targets tighter than their targets endogenous ligands, validating the peptides potential as lead therapeutic candidates. We provide an implementation of DexDesign in the free and open source computational protein design software OSPREY.

bioinformatics↗